Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Square Pharmaceuticals's OCF Margin % or its related term are showing as below:
DHA:SQURPHARMA'
s OCF Margin % Range Over the Past 10 Years
Min: 14.08 Med: 23.45 Max: 28.14
Current: 26.7
During the past 13 years, the highest OCF Margin % of Square Pharmaceuticals was 28.14%. The lowest was 14.08%. And the median was 23.45%.
DHA:SQURPHARMA's OCF Margin % is ranked better than 89.11% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.16
vs DHA:SQURPHARMA: 26.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:SQURPHARMA vs ZTS, UTHR: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a OCF Margin % of 17.90% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Square Pharmaceuticals and its competitors. This is 24% below median its historical median of 23.45. Over the past decade, Square Pharmaceuticals' OCF Margin % has ranged from 14.08 to 28.14. According to the industry distribution chart, Square Pharmaceuticals ranks #105 out of 964 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Square Pharmaceuticals' OCF Margin % too high?
Square Pharmaceuticals' current OCF Margin % of 17.90% is 24% below median its 10-year median of 23.45. Over the past 10 years, this metric has ranged from a low of 14.08 to a high of 28.14. The Drug Manufacturers industry median OCF Margin % is 10.16. Square Pharmaceuticals' value of 17.90% is 76.2% above this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #105 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #105 out of 964 companies for OCF Margin %. This places Square Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.16. Square Pharmaceuticals' value of 17.90% is 76.2% above this benchmark. Historically, Square Pharmaceuticals' own OCF Margin % has ranged from 14.08 to 28.14 over the past decade. While the company's 10-year median is 23.45 vs. the industry median of 10.16, Square Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current OCF Margin % of 17.90% is 76.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current OCF Margin % is 17.90%, which is 24% below median its own 10-year median of 23.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current OCF Margin % is 17.90%, which is 24% below median its 10-year median of 23.45 and 76.2% above the Drug Manufacturers industry median of 10.16. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current OCF Margin % is 17.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
OCF Margin %: 17.90% (24% below median its 10-year median of 23.45)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 76.2% above the Drug Manufacturers median (#105 of 964)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
